Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: LTBI Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

NCT03510468
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT

NCT01582711
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine
Behavioral · Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Latent TB Infection for Jailed Persons

NCT00128206
View directory record Official record
Conditions
Tuberculosis
Interventions
Isoniazid, Rifampin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 17, 2026, 6:57 PM EDT
Withdrawn Not applicable Interventional

Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation

NCT00424684
View directory record Official record
Conditions
Chronic Liver Disease, TB
Interventions
collection of blood sample
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 17, 2026, 6:57 PM EDT
Completed No phase listed Observational Results available

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

NCT02687529
View directory record Official record
Conditions
Tuberculosis
Interventions
CST001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

NCT05526911
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876, Midazolam, Digoxin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 6:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Screening With Portable X-rays for Rapid Recognition of TB

NCT07737275
View directory record Official record
Conditions
Tuberculosis (TB), Tuberculosis Infection, Latent, HIV (Human Immunodeficiency Virus)
Interventions
Mobile chest radiography for tuberculosis screening
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 6:57 PM EDT
Completed No phase listed Observational

Immune Response to Mycobacterium Tuberculosis Infection

NCT00257907
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VDOT for Monitoring Adherence to LTBI Treatment

NCT02641106
View directory record Official record
Conditions
Tuberculosis, Latent Tuberculosis Infection
Interventions
Video Directly Observed Therapy, In-Person DOT
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging

NCT02690818
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Regularly scheduled LTBI medication reminder text messages
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 17, 2026, 6:57 PM EDT
Withdrawn No phase listed Observational

Video Based Directly Observed Therapy for Latent TB

NCT03783728
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine 600 mg orally, Isoniazid 900 mg orally, Pyridoxine 50 mg orally
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

NCT01404312
View directory record Official record
Conditions
Tuberculosis, HIV Infections
Interventions
Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 6:57 PM EDT
Completed No phase listed Observational

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

NCT01622140
View directory record Official record
Conditions
Latent Tuberculosis Infection, Tuberculosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
21,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 17, 2026, 6:57 PM EDT
Completed No phase listed Observational

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

NCT00763295
View directory record Official record
Conditions
Latent Tuberculosis, HIV Infections
Interventions
T-Spot.TB test
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV

NCT03702049
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
Nurse-led Community Health Worker TBI (RN/CHW TBI) program
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 17, 2026, 6:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Immunobiology of Diabetes and Tuberculosis

NCT00568854
View directory record Official record
Conditions
Tuberculosis, Diabetes Mellitus
Interventions
BCG
Biological
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 17, 2026, 6:57 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

NCT04453293
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
BCG (Tokyo 172) vaccine, Placebo
Biological · Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 6:57 PM EDT
Recruiting Phase 2Phase 3 Interventional

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doravirine, Rifapentine and Isoniazid Interaction

NCT03886701
View directory record Official record
Conditions
Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
Interventions
Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 17, 2026, 6:57 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

NCT05766267
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis Infection
Interventions
Rifabutin, Delamanid, Bedaquiline, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits

NCT00804713
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
BST, TST, QFT, T-spot
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
2,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 17, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection

NCT00164450
View directory record Official record
Conditions
Tuberculosis
Interventions
Isoniazid, Rifapentine
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
2 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 6:57 PM EDT
Completed No phase listed Observational Results available

Evaluation of the QuantiFERON-TB Test.

NCT02142894
View directory record Official record
Conditions
Tuberculosis
Interventions
CST001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 17, 2026, 6:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation of the VIDAS TB-IGRA Assay.

NCT04048018
View directory record Official record
Conditions
Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions
Blood draw and IGRA test
Diagnostic Test
Lead sponsor
BioMérieux
Industry
Eligibility
2 Years and older
Enrollment
2,401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 17, 2026, 6:57 PM EDT